Jean Franchi
Directeur Financier/CFO chez DISC MEDICINE, INC.
Fortune : 1 M $ au 30/04/2024
Postes actifs de Jean Franchi
Sociétés | Poste | Début | Fin |
---|---|---|---|
BIODESIX, INC. | Directeur/Membre du Conseil | 01/04/2020 | - |
Independent Dir/Board Member | 01/04/2020 | - | |
DISC MEDICINE, INC. | Directeur Financier/CFO | 07/02/2024 | - |
Treasurer | 07/02/2024 | - | |
VectorY BV
VectorY BV Miscellaneous Commercial ServicesCommercial Services VectorY BV is a biotech company based in Amsterdam, Netherlands, that is dedicated to developing transformative medicines for people with neurodegenerative diseases such as ALS, Huntington's, and Parkinson's. VectorY's platform combines the promise of precise therapeutic antibodies with one-time AAV-based delivery to the CNS, enabling long-lasting CNS treatment after a single administration using cutting-edge antibody, AAV, and manufacturing technologies. The Dutch company's unique in-house expertise in antibodies, AAV vectors, protein degradation, manufacturing, and neuroscience drives the rapid development of much-needed disease-modifying therapies for neurodegenerative diseases. The company was founded by Sander J. van Deventer and Pavlina Konstantinova, with Sander J. van Deventer serving as the CEO since incorporation. | Directeur/Membre du Conseil | - | - |
Flamingo Therapeutics BV
Flamingo Therapeutics BV Miscellaneous Commercial ServicesCommercial Services Flamingo Therapeutics BV is a Belgian company that specializes in developing RNA-targeted therapies for oncology. The company is based in Leuven, Belgium and was founded by Mike Garrett and Floor Stam. Flamingo is dedicated to delivering therapeutic benefit to patients living with cancer and believes that their programs and approach can successfully address large unmet medical needs where RNA-targeting can be effective. The company's clinical-stage pipeline focuses on targeting undruggable transcription factors and splice variants. The CEO is Stephane van Rooijen. | Directeur/Membre du Conseil | - | - |
Dynacure SA
Dynacure SA Medical/Nursing ServicesHealth Services Dynacure SA is a clinical-stage company, which engages in developing and commercializing novel therapies to transform the lives of patients with rare diseases who have limited or no treatment options. Its product includes, DYN101, an antisense oligonucleotide, or ASO, designed to be a disease-modifying medicine for treatment of the majority of ntronuclear myopathies patients with multiple mutations in adult and pediatric populations. The company was founded by Belinda Cowling in 2016 and is headquartered in Illikirch-Graffenstaden, France. | Directeur/Membre du Conseil | 21/01/2021 | - |
Historique de carrière de Jean Franchi
Anciens postes connus de Jean Franchi
Sociétés | Poste | Début | Fin |
---|---|---|---|
REPLIMUNE GROUP, INC. | Compliance Officer | 09/12/2019 | 02/06/2023 |
Directeur Financier/CFO | 09/12/2019 | 02/06/2023 | |
Secrétaire Général | 09/12/2019 | 02/06/2023 | |
Treasurer | 09/12/2019 | 02/06/2023 | |
VISIONEERING TECHNOLOGIES, INC. | Directeur/Membre du Conseil | 19/12/2017 | 19/12/2022 |
Independent Dir/Board Member | 19/12/2017 | 19/12/2022 | |
BIOPHYTIS S.A. | Directeur/Membre du Conseil | 16/06/2017 | 07/07/2021 |
Independent Dir/Board Member | 16/06/2017 | 07/07/2021 | |
MERRIMACK PHARMACEUTICALS, INC. | Comptroller/Controller/Auditor | 21/08/2017 | 28/06/2019 |
Directeur Financier/CFO | 21/08/2017 | 28/06/2019 | |
Treasurer | 21/08/2017 | 28/06/2019 | |
░░░░░░░░░░░░░ ░░░░░░░░░ ░░ ░░░ ░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░░░░░ ░░░░░░░░░░░░ ░░░ | ░░░░░░░░ ░░ ░░░░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░░░░░ ░░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ | |
░░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ | |
░░░░ ░░░░░ ░░░░░░░░░ ░░░░ | ░░░░░░░░ ░░ ░░░░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░░░ ░░░░░ | ░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░░ ░░ | ░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░ | - | - |
░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ | |
░░░░░ ░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - | - |
░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - | - |
Formation de Jean Franchi
Hofstra University | Undergraduate Degree |
Statistiques
Internationale
Etats-Unis | 13 |
France | 4 |
Belgique | 2 |
Opérationnelle
Director/Board Member | 7 |
Director of Finance/CFO | 5 |
Treasurer | 4 |
Sectorielle
Health Technology | 10 |
Health Services | 5 |
Commercial Services | 3 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Sociétés cotées | 6 |
---|---|
BIOPHYTIS S.A. | Health Technology |
MERRIMACK PHARMACEUTICALS, INC. | Health Technology |
VISIONEERING TECHNOLOGIES, INC. | Electronic Technology |
REPLIMUNE GROUP, INC. | Health Technology |
BIODESIX, INC. | Health Services |
DISC MEDICINE, INC. | Health Technology |
Entreprise privées | 10 |
---|---|
Good Start Genetics, Inc.
Good Start Genetics, Inc. Medical/Nursing ServicesHealth Services Good Start Genetics, Inc. operates as a molecular diagnostics firm. It offers pre-pregnancy diagnostic test services to screen a panel of genetic disorders. The firm also provides clinical laboratory and genetic counseling support services. The company was founded by Eric Boutin, Paris Wallace, and Gregory J. Porreca in December 2007 and is headquartered in Cambridge, MA. | Health Services |
bioMérieux, Inc.
bioMérieux, Inc. Medical SpecialtiesHealth Technology bioMérieux, Inc. develops in-vitro diagnostics solutions. It offers microbiological testing solutions for medical and industrial applications. The company was founded on December 31, 1986 and is headquartered in Durham, NC. | Health Technology |
Wyeth Corp.
Wyeth Corp. Pharmaceuticals: MajorHealth Technology Wyeth LLC develops, manufactures, and distributes pharmaceuticals and biological substances. The company was founded in 1926 and is headquartered in Madison, NJ. | Health Technology |
Dimension Therapeutics, Inc.
Dimension Therapeutics, Inc. BiotechnologyHealth Technology Dimension Therapeutics, Inc. engages in the development of novel treatments for rare diseases. Its activities include discoveries and development of therapeutic products for people living with rare diseases associated wit the liver and caused by genetic mutations. The company was founded by Ben Auspitz in June 20, 2013 and is headquartered in Cambridge, MA. | Health Technology |
International Institute of New England, Inc.
International Institute of New England, Inc. Services to the Health IndustryHealth Services International Institute of New England, Inc. operates as a non-profit organization serving immigrants, refugees, asylees, and other vulnerable populations. Its services include refugee resettlement, case management, health services navigation, employment, education and literacy and citizenship programming. The company was founded in 1910 and is headquartered in Boston, MA. | Health Services |
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Health Technology |
Dynacure SA
Dynacure SA Medical/Nursing ServicesHealth Services Dynacure SA is a clinical-stage company, which engages in developing and commercializing novel therapies to transform the lives of patients with rare diseases who have limited or no treatment options. Its product includes, DYN101, an antisense oligonucleotide, or ASO, designed to be a disease-modifying medicine for treatment of the majority of ntronuclear myopathies patients with multiple mutations in adult and pediatric populations. The company was founded by Belinda Cowling in 2016 and is headquartered in Illikirch-Graffenstaden, France. | Health Services |
Sanofi SA | Health Technology |
Flamingo Therapeutics BV
Flamingo Therapeutics BV Miscellaneous Commercial ServicesCommercial Services Flamingo Therapeutics BV is a Belgian company that specializes in developing RNA-targeted therapies for oncology. The company is based in Leuven, Belgium and was founded by Mike Garrett and Floor Stam. Flamingo is dedicated to delivering therapeutic benefit to patients living with cancer and believes that their programs and approach can successfully address large unmet medical needs where RNA-targeting can be effective. The company's clinical-stage pipeline focuses on targeting undruggable transcription factors and splice variants. The CEO is Stephane van Rooijen. | Commercial Services |
VectorY BV
VectorY BV Miscellaneous Commercial ServicesCommercial Services VectorY BV is a biotech company based in Amsterdam, Netherlands, that is dedicated to developing transformative medicines for people with neurodegenerative diseases such as ALS, Huntington's, and Parkinson's. VectorY's platform combines the promise of precise therapeutic antibodies with one-time AAV-based delivery to the CNS, enabling long-lasting CNS treatment after a single administration using cutting-edge antibody, AAV, and manufacturing technologies. The Dutch company's unique in-house expertise in antibodies, AAV vectors, protein degradation, manufacturing, and neuroscience drives the rapid development of much-needed disease-modifying therapies for neurodegenerative diseases. The company was founded by Sander J. van Deventer and Pavlina Konstantinova, with Sander J. van Deventer serving as the CEO since incorporation. | Commercial Services |
- Bourse
- Insiders
- Jean Franchi
- Expérience